Merkel cell carcinoma is a type of skin cancer that develops as painless bumps, due to sun exposure. Bumps can be red-violet coloured or skin coloured and grow rapidly surrounding lymph nodes. The risk factors associated with merkel cell carcinoma are excessive sun exposure, chronic immune suppression, merkel cell polyomavirus, and aging. The main cause of occurrence of merkel cell carcinoma is somatic mutations in DNA. The tumour formed in merkel cell carcinoma, is comprised of small uniform round blue cells that are arranged in the cluster, bands, and cords forms. Millennium Pharmaceuticals, Inc. is in the process of developing MLN0128 as a mTOR protein inhibitor for the treatment of merkel cell carcinoma. Bristol-Myers Squibb Company is in the process of developing ipilimumab as a cytotoxic T-lymphocyte antigen 4 inhibitor for the treatment of merkel cell carcinoma. Some of the companies having the pipeline of merkel cell carcinoma include Millennium Pharmaceuticals, Inc., NantKwest, Inc., Bristol-Myers Squibb Company and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.